- $15.9 BnWorld market, 2023
- $29.8 BnProjected, 2033
- 6.5%Growth a year (CAGR)
- –Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$6.7 Bn
4.5% a year · 42% of the world -
2
China
$1.3 Bn
8% a year · 8% of the world -
3
Canada
$1.3 Bn
6.5% a year · 8% of the world -
4
Japan
$988 Mn
7% a year · 6.2% of the world -
5
Germany
$582 Mn
4.7% a year · 3.7% of the world -
6
France
$437 Mn
5.5% a year · 2.8% of the world -
7
UK
$413 Mn
4.5% a year · 2.6% of the world -
8
Brazil
$397 Mn
7.5% a year · 2.5% of the world -
9
Italy
$381 Mn
6% a year · 2.4% of the world -
10
Ecuador
$318 Mn
7.1% a year · 2% of the world
Insulin Delivery Devices by country and region
Spain
India
Saudi Arabia
Mexico
Australia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
New Zealand
Russia"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 3,597 papers since 2021
- Diabetic ketoacidosis associated with the reuse of single-use materials in a patient with type 1 diabetes mellitus treated with an advanced hybrid closed-loop system: A case report. Endocrinologia, diabetes y nutricion, 2026
- Postprandial glucose management of people with insulin-treated diabetes. Frontiers in endocrinology, 2026
- Artificial Intelligence in Paediatric Endocrinology: A Narrative Review from the Perspective of Early-career Clinicians and Researchers. Hormone research in paediatrics, 2026
- Automated Insulin Delivery in Pregnancies Complicated by Type 1 Diabetes: A Real World Observational Study of Available Systems. The Australian & New Zealand journal of obstetrics & gynaecology, 2026
- [A rare cause of ketoacidosis: Rapunzel syndrome]. Innere Medizin (Heidelberg, Germany), 2026
Patients: Diabetes (adults)
| Place | Value | Year |
|---|---|---|
| World | 14.1 | 2022 |
| Australia | 8.1 | 2022 |
| Brazil | 12.9 | 2022 |
| Canada | 6.8 | 2022 |
| China | 11.2 | 2022 |
| Ecuador | 12.7 | 2022 |
| Egypt | 27.8 | 2022 |
| France | 2.7 | 2022 |
| Germany | 6.6 | 2022 |
| India | 22.6 | 2022 |
| Italy | 7.2 | 2022 |
| Japan | 6.4 | 2022 |
| Kenya | 5.6 | 2022 |
| Malaysia | 26.7 | 2022 |
| Mexico | 14.3 | 2022 |
| New Zealand | 9.0 | 2022 |
| Philippines | 13.2 | 2022 |
| Russia | 8.1 | 2022 |
| Saudi Arabia | 20.8 | 2022 |
| Singapore | 13.1 | 2022 |
| South Africa | 13.9 | 2022 |
| Spain | 3.6 | 2022 |
| Thailand | 12.3 | 2022 |
| UAE | 26.1 | 2022 |
| UK | 8.8 | 2022 |
| US | 12.5 | 2022 |
Compare Insulin Delivery Devices side by side
Key companies in Insulin Delivery Devices
Novo Nordisk A/S
Medtronic
Sanofi S.A.
Eli Lilly and Company
Wockhardt Ltd.
Quick answers
How big is the Insulin Delivery Devices market?
The world Insulin Delivery Devices market was worth about $15.9 Bn in 2023 and is projected to reach $29.8 Bn by 2033, growing 6.5% a year (CAGR).
Which country has the largest Insulin Delivery Devices market?
The US is the largest of the 24 countries we cover, at $6.7 Bn in 2023. India grows fastest, at 9.5% a year.
How much research is published on Insulin Delivery Devices?
PubMed lists about 3,597 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Patients: WHO Global Health Observatory. Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.